Scholarly Research Journal for Interdisciplinary Studies
Online ISSN 2278-8808, SJIF 2021 = 7.380,
http://www.srjis.com/issues_data?issueId=218
Peer Reviewed, Refereed & Indexed Journal, JULY-AUG, 2023, Vol- 12/78
https://doi.org/10.5281/zenodo.8314288

ROLE OF LINAGLIPTIN IN THE MANAGEMENT OF DIABETES

Dr. Pushkaraj Kulkarni, MD
Associate professor, Department of Kaychikitsa
Siddahakala Ayurveda mahavidyalaya , Sangamner maharashtra
pushkarajk19@gmail.com

Paper Received On: 21 AUG 2023
Peer Reviewed On: 27 AUG 2023
Published On: 01 SEPT 2023

Abstract

Linagliptin has lately been approved for use in the USA, Japan, and Europe for treating T2DM. The medicine has been approved for monotherapy or in combination with other generally specified specifics for T2DM, similar as metformin, sulfonylureas, and pioglitazone. Linagliptin is an oral antihyperglycemic agent that widely inhibits the enzyme dipeptidyl peptidase- 4 (DPP- 4). Inhibition of DPP- 4 increases the situations of the incretin hormones glucagon- suchlike peptide and glucose-dependent insulinotropic polypeptide by precluding their declination. Linagliptin is an oral, formerly-daily, antihyperglycemic agent that significantly reduces glycated haemoglobin (HbA1c) when used alone or in combination with other antidiabetic medicines in people with type 2 diabetes. Pharmacokinetics, similar as the lack of renal excretion, distinguishes linagliptin from other gliptins. Cases with type 2 diabetes mellitus (T2DM) constantly bear multiple curatives to effectively control hyperglycaemia, and numerous new agents for glucose control have been developed over the once many decades. Linagliptin is a lately approved oral antidiabetic medicine that acts by inhibiting the enzyme dipeptidyl peptidase- 4 (DPP- 4). Unlike other DPP- 4 impediments, linagliptin is excreted primarily via the enterohepatic system, and can be used without cure adaptation in cases with renal or hepatic impairment. Linagliptin was approved by the US Food and Drug Administration grounded on a large development program, including four vital trials in cases with T2DM, assessing the efficacity and safety of linagliptin when used as monotherapy or in combination with other oral antidiabetic medicines.

The present paper focused on the study of role of linagliptin in the management of diabetes with prime objectives are (i) To understand the importance of linagliptin in the management (ii) To analyses the Role of Linagliptin in the Management of Diabetes (iii) To discuss the importance of linagliptin in the management of diabetes.

The methodology of the research is a different type involving an interpretative, conversation, observations and study secondary sources, like books, articles, journals, thesis, university news, expert opinion, and websites etc.

Key Words: *Role of Linagliptin, Management of Diabetes*

Introduction:

Linagliptin was associated with significant advancements in glycosylated haemoglobin, dieting tube glucose and postprandial glucose, and further cases entering linagliptin showed meaningful advancements and achieved targets for glycosylated haemoglobin. Linagliptin was well permitted, with an adverse event profile analogous to that of placebo, and low rates of hypoglycaemic events. Taken together, the vital trials confirm linagliptin is effective and safe in cases with T2DM the convenience of oral dosing with no demand for cure adaptation in cases with renal or hepatic impairment make linagliptin a precious option when considering curatives for cases with T2DM.

The nature of clinical trials can alter cases' geste, similar as diet, exercise or compliance with drug, which may in turn impact blood glucose control. To offset this, all trials included a 2- week open- marker placebo run- in to allow cases to acclimatize to trial conditions. All cases were handed with standard diet and exercise comforting as well as outfit for home blood glucose monitoring at the launch of the run- heft.

To study the efficacity and safety of linagliptin monotherapy, grown-ups with T2DM who were treatment naïve or who had been treated with one oral antidiabetic medicine (OAD; except a thiazolidinedione because of the long flop demanded for these specifics) were signed. Treatment- naïve cases were eligible if they had webbing HbA1c situations between7.0 and10.0, while preliminarily treated cases were eligible with webbing HbA1c situations between6.5 and9.0, and between7.0 and10.0 after a 4- week flop of their other OAD. Cases who were treatment- naïve entered directly into the 2- week open- marker placebo run- in after webbing; preliminarily treated cases entered the run- in after their flop.

Importance of Linagliptin in the Management of Diabetes:

- Linagliptin, one of the five dipeptidyl peptidase- 4 impediments available, has lately entered the request both in the US and in utmost European countries for treatment of type 2 diabetes mellitus.
- It presents a xanthine- grounded structure, and is characterized by unique pharmacokinetics, with non-linear profile, long terminal half- life allowing dragged exposure to the medicine.



Figure 1. Linagliptin

- It's excluded predominately through the intestinal tract and only minimally into urine, so that it can be administered, without any cure adaptation, in conditions of renal impairment.
- Linagliptin is effective in modifying all parameters of hyperglycemia either in monotherapy, or as add on remedy, together with metformin or a sulfonylurea.
- It also exhibits a good tolerability profile with many side goods, absence(when used in monotherapy), or low threat(when in combination with a sulfonylurea) of hypoglycemia.
- More importantly it has a weight neutral effect. A comprehensive report of the literature on linagliptin is handed, paying attention in particular to preclinical studies, relations with other medicines, safety and tolerability, and results attained in beast models that punctuate parcels of linagliptin suggestive of implicit fresh uses.
- Particularly promising appear the data demonstrating a positive effect of linagliptin on metabolic dysfunction and renal and/ or cardiovascular damage together with more lately reported goods of linagliptin on towel form and neuroprotection.

Objectives of the Study:

The present study has the following objectives-

Obj. 1: To understand the importance of linagliptin in the management.

Obj. 2: To analyses the Role of Linagliptin in the Management of Diabetes

Obj. 3: To discuss the importance of linagliptin in the management of diabetes.

Role of Linagliptin in the Management of Diabetes:



Figure 2. Linagliptin: Hyperglycaemia- Management in Diabetes

Pharmacokinetics & pharmacodynamics of linagliptin:

Linagliptin is an orally available xanthine □ grounded noncovalent asset of DPP □ 4 with a molecular mass of472.5 Da. Of all approved DPP □ 4 impediments, linagliptin has the loftiest energy for inhibiting the enzymatic exertion of DPP □ 4 competitively and reversibly with an IC50 of roughly 1 nM(compared with1.75 nM for teneligliptin,3.8 nM for anaglip drum,6.9 nM for alogliptin, 19 nM for sitagliptin, 62 nM for vildagliptin and 50 nM for saxaglip drum). The selectivity of linagliptin for DPP □ 4 is 40,000 □ fold advanced than towards DPP □ 8 and 10,000 □ fold advanced than towards DPP □ 9. Lina □ gliptin shows veritably little commerce with other protease enzymes similar as aminopeptidase N or P, plasmin, prolyl □ oligopeptidase, thrombin and trypsin (52). likewise, linagliptin has no significant inhibitory effect on the CYP450 enzymes (IC50 50 μM)(53,54).

Immersion:

In humans, the bioavailability of linagliptin is roughly 30, which is lower than that of vildagliptin (85) or sitagliptin(87) (55 – 57). High □ fat reflections reduce the outside attention (Cmax) by 15 and increase the area under the wind (AUC) by 4, and input of a high □ fat mess reduces the rate of linagliptin immersion, but has no influence on the extent of immersion; these findings suggests that food has no applicable influence on the efficacity of linagliptin. After oral input, linagliptin is fleetly absorbed, and the peak tube attention (Tmax) was determined at a time interval of0.7 – 3 hours after administration; the mean tube AUC was 139 nmol * h/ l and the Cmax was8.9 nmol/ l. The Tmax didn't differ between healthy and Type 2 diabetic subjects after single and multiple boluses of linagliptin.



Figure 3. Linagliptin Structure

Distribution:

The mean apparent volume of distribution at steady state following a single intravenous cure of linagliptin 5 mg to healthy subjects is roughly 1110 l, indicating expansive tis □ sue distribution (59). In beast studies it was shown that tube protein list of linagliptin is attention dependent, dwindling from roughly 99 at 1 nmol/ l to 75-89 at 30 nmol/ l, reflecting achromatism of binding to DPP □ 4 with adding attention of linagliptin. At high attention, where DPP □ 4 is completely impregnated, 70 to 80 of linagliptin remains bound to tube proteins and 20 to 30 is footloose in tube. Tube list isn't altered in cases with renal or hepatic impairment, and there's high □ affinity list to the target DPP □ 4 in different apkins, generally in the order. Steady □ state attention of linagliptin are reached within 2-5 days after formerly

diurnal administration, with an elimination half life between 113 and 130 hours. These pharmacokinetic data are valid for all ethnical groups studied.

Metabolism:

In vivo, linagliptin is hardly metabolized and approximately 90% of the compound is excreted in an unchanged form by the hepatobiliary route via the faeces. The elimination is rather slow, with a half□life of 70–80 h. Approximately 1–6% of the dose is eliminated via the renal route and excreted in the urine when standard doses of 5 mg are given.

After oral administration of a single 5□mg dose to healthy subjects, the Tmax of linagliptin occurred at approximately 1.5 h; the mean plasma AUC was 139 nmol*h/l and the Cmax was 8.9 nmol/l. Plasma concentrations of linagliptin decline in a biphasic manner with a long terminal half□life (>100 h) related to the saturable binding of linagliptin to DPP□4. The effective half□life for accumulation of linagliptin, as determined from oral administration of mul□ tiple doses of linagliptin 5 mg, is approximately 12 h. After once□daily dosing, steady□state plasma concentrations of linagliptin 5 mg are reached by the third dose, and the Cmax and AUC increased by a factor of 1.3 at steady state com□ pared with the first dose. The intra□ and inter□ subject coefficients of variation for linagliptin AUC were small (12.6 and 28.5%, respectively). The plasma AUC of linagliptin increases in a less than dose□proportional manner in the dose range of 1–10 mg. The pharmacokinetics of linagliptin are similar in healthy subjects and in patients with Type 2 diabetes. Linagliptin exposure (AUC and Cmax) increases less than proportionally with the dose.

Linagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes. This drug should not be used in patients with type-1 diabetes or in those with diabetic ketoacidosis. Linagliptin has not been studied in combination with insulin.

Future perspective:

To date, there is a lack of long□term safety data with the DPP□4 inhibitors, especially those related to generalized DPP□4 inhibition. Studies of longer duration and careful post approval surveillance are needed, and have been requested by the FDA. Studies are now underway to assess the safety of linagliptin, particularly in subjects with multiple cardiovascular risks. These large□scale long□duration studies will not only characterize the long□term safety of linagliptin, but should also shed light on possible cell preservation. Further data to support the concept of cell preservation would markedly enhance the desirability of the use of linagliptin and other DPP□4 inhibitors. Initial data also suggest fewer cardiac events in linagliptin□treated patients compared with other comparators. Confirmation in long□ term studies.



Conclusion:

Linagliptin is a highly selective inhibitor of the enzyme DPP-4. It is one of several agents of this class now available for treatment of Type 2 diabetes. This review is based on a PubMed search, clinical trials and personal experience with linagliptin. In addition, the US FDA approval folder on linagliptin was obtained under the Freedom of Information Act and analysed. The pharmacokinetics and pharmacodynamics of linagliptin are reviewed. The glucose-lowering effect of this agent is discussed both as a monotherapy and in combination with metformin, sulfonylurea, pioglitazone and insulin. The potential adverse effects of linagliptin are summarized. Linagliptin is an additional choice in the group of DPP-4 inhibitors. Unlike other DPP-4 inhibitors, linagliptin is excreted chiefly via the enterohepatic system and can be used without dose adjustment in patients with renal or hepatic impairment. As a group, the DPP-4 inhibitors have a relatively modest glucose-lowering effect. The primary use of DPP-4 inhibitors is in combination with other hypoglycaemic agents, mainly metformin. Their principal advantage is a low incidence of hypoglycaemia, making these agents desirable in patients such as the elderly and those with cardiac disease. A greater use of linagliptin and other DPP-4 inhibitors will occur if long-term studies show extended retention of insulin secretory capacity and/or reduced cardiac events over time with these agents.

References:

Horie Y, Kanada S, Watada H, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double- blind, placebo-controlled phase II a study in Japanese type 2 diabetes patients. Clin Ther. 2011;33:973–989.

Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2010;19:133–140.

Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13:542–550. [PubMed] [Google Scholar]

Del PS, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13:258–267.

Forst T, Pfutzner A. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opin Pharmacother. 2012;13:101–110.

Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71:1441–1467

Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother. 2012;13:81–99.

Retlich S, Duval V, Ring A, et al. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg–10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase- 4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clin Pharmacokinet.

Huttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008;48:1171–1178.

Graefe-Mody U, Giessmann T, Ring A, Iovino M, Woerle HJ. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin Ther. 2011;33:1096–1103.

Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase- 4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11:786–794.

Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38:667–678.

Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem. 2007;50:6450–6453. [PubMed] [Google Scholar]

Barnett AH. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.

Schernthaner G, Barnett AH, Emser A, et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14:470–478.

Graefe-Mody U, Rose P, Ring A, Zander K, Iovino M, Woerle HJ. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. Drug Metab Pharmacokinet. 2011;26:123–129.

Cite Your Article as:

Pushkaraj Kulkarni Ph.D. (2023). ROLE OF LINAGLIPTIN IN THE MANAGEMENT OF DIABETES. Scholarly Research Journal for Interdisciplinary Studies, 12(78), 566–572.
https://doi.org/10.5281/zenodo.8314288